ANZICS CTG Endorsed Study

TARGET PPP (NZ) / Nutrition prescription in ANZ: PPD (AUS)

TARGET Point Prevalence Study – New Zealand / Nutrition prescription in Australian and New Zealand intensive care units: A point prevalence audit – Australia

Study Description

The Augmented versus Routine approach to Giving Energy Trial (TARGET) was a 4000-patient randomised controlled, multicentre trial comparing augmented enteral energy delivery to standard care on 90-day survival. TARGET completed recruitment in November 2017. In order to evaluate the influence TARGET has had on current practice and may have on future practice, an understanding of current nutrition practices in Australian and New Zealand intensive care units (ICUs) must be obtained. Data on protein prescription will also guide a Phase III trial on protein delivery in critically ill adults.

This is a prospective, observational, multicentre, single-day, point-prevalence study. The objective is to determine common nutrition (energy and protein) prescriptions across Australia and New Zealand ICUs.

Management Committee

Marianne Chapman (Co-Chair), Sandra Peake (Co-Chair), Lee-anne Chapple, Andrew Davies, Donna Goldsmith, Sue Huckson, Sally Hurford, Lorraine Little (Project Manager [NZ]), John Moran, Anneleen Neuts, Stephanie O’Connor (Project Manager [AUS]), and Patricia Williams.

Administering Institution

Central Adelaide Local Health Network


This study will be conducted in collaboration with the TARGET Investigator Group.

Sample Size

All adult patients (≥16 years of age) present in participating ICUs at 10:00AM on the 31st JULY 2018 enrolled. Participating sites (28 in Australia and 11 in New Zealand).


(NHMRC: NCT02306746, APP1078026, >$3.5m, 2015-19, CIA-Chapman); Per patient payments and CORE database set-up costs will be provided from the TARGET program grant

Project Status as of June 2019

568 patients have been included in the point prevalence study from 39 sites. Data has been entered and the first stage of data cleaning has occurred for 481 patients.




Lee-anne Chapple (email)

Stephanie O’Connor (email)